Google Search

Search

Already a Member ?

Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Drug Intermediates, Speciality Chemicals, Raw Materials, Fine and Specialty Chemicals Intermediates, Pharmaceutical Bulk Drugs

Indian drugs and pharmaceutical industry has advanced perceptibly and is getting ready  for the new patent regime and  to withstand global competition, which is expected to be unleashed by new winds of liberalisation - a new era of liberalisation - much different from what was ushered in since the conclusion of the Uruguay Round and the establishment of the World Trade Organisation.

The industry has been expanding at annual rates ranging between 8 to 10% (against global growth rate of 6%).  According to a study  by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of  $25 billion (Rs 1200 billion) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing.  The market for bulk drugs and formulations had increased from about Rs 103  billion in 1990-91 to an estimated Rs 435  billion at the end of 2003-04.  The prices of Indian essential drugs are among the lowest in the world. Apart from strides made by the industry in the last half-a-century, lower production cost due to reverse engineering and low R&D outlays has been a major factor in keeping the prices under check.

The global pharmaceutical industry is estimated at $ 300 billion, not all representing cross-border trade.  India's measly share of $ 1.5 billion in global trade represents an untapped potential. Under the regime of economic liberalisation underway since early 1990s, the drugs and pharmaceutical sector witnessed initiatives at fresh investment in the sector. Nearly 1735 investment proposals of the order of around Rs 166  billion were initiated. The foreign collaboration proposals approved numbered around 425 with a foreign direct investment  (FDI) component of over Rs 25 billion. The pharmaceuticals have figured high on the export front. In 2001-02,  the sector was  estimated to have registered a growth of 17.6% at around Rs 20.3 billion.

In the wake of economic liberalisation, many a  overseas players  returned or contemplated returning to India. These include Ivox Corp (USA),  Taro Pharmaceuticals (Israel) and Merck (USA). These are out either to set shop or looking for acquisitions in India. Hexal AG of Germany has established a liaison office in India. MILLIONCs like Rocha, Bayer, Aventis and Chiron are making India a regional hub for bulk drugs. 

The Export Import Bank of India (Exim Bank) had  doubled its corpus for the pharmaceutical industry to Rs 2 billion as a result of increased activity in the industry, especially in the external sector. The fund is used for the development and commercialisation of the new products and applications, significant improvement in the existing design of  products, setting up and expansion of pilot plants, research studies for obtaining regulatory approvals, cost of filing and managing international patent and R&D Centres.

It needs, however, to be recognised that the presence  of small scale manufacturers has resulted, on the one hand,  in a highly fragmented industry, and on the other, it has made it possible to supply a near 100,000 drugs including vitamins, antibiotics, antibacterials, cardio-vascular and other essential drugs. These account for nearly 37% of the market.  While each of about 80% of the manufacturers has annual sales below a billion rupees, top ten companies are known to control over 30% of the market. At present there are more than 20,000 players in the country.

The major players are: Alembic Chem, Aurobindo Pharma, Cipla, Dr. Reddy's, FDC, IPCA Labs, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Morepan Labs, Nicholas Piramal, Ranbaxy Labs, Sun Pharma, Themis Medicare, GlaxoSmithkline, Astrazeneca, Aventis, E-Merck, Torrent Pharma, TTK Healthcare, Unichem Labs,  Wockhardt  and  Zandu Pharma.  Until recently, only a few of the Indian companies had gone into any serious R&D activity. Much of the effort was directed to affordable analogue research. The R&D level in the country is low with even well-placed pharma companies spending less than 2% of turnover on R&D. MILLIONCs are known to contribute as much as 10% or more of their turnover to R&D.  While India is very strong in process chemistry, biology and applied bio-chemistry, initiatives at all levels - government, academia, private sector - involving heavy financial outlays, are called for.

Ayurveda continues to remain a preferred system of medicine for a vast segment of population in the country. The country has over 400,000 registered practitioners of the Indian system of medicine. Around 170 institutes properly affiliated to various universities impart under- or post-graduate courses each year. These institutes churn out some 5,500 fresh practitioners. The practitioners are supported by 12,000 dispensaries and 2,100 beds available for ayurveda treatment countrywide. The emerging biotechnology sector has already taken by storm and is offering sops to states to make these as the thriving ground for the highly potential segment in medicare.

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 13 of 21 | Total 201 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Saline and Dextrose Fluid (IV) - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue

The growth of I.V. fluid manufacturing was faster than the growth rate of drugs. These IV fluids are the best alternative which can yield sudden result in the health of a patient by replenishing the body fluids. Liquid glucose and dextrose are being produced in the organized sector. The gap between the production and consumption of liquid glucose is removed by the import. I.V. fluid demand is normally linked to the number of hospital beds. Observations show that 18 bottles of I.V. fluids are consumed per bed per month in the country. The demand is estimated to increase at a rate of 9 to 12% per annum. The present demand level is estimated to be around 2200 lakh bottles per annum. Demand is high Uttar Pradesh, Rajasthan, Haryana, Bihar, Madhya Pradesh and West Bengal. North India alone account for one third of the total demand in the country.
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: 1.00%
Add to Inquiry Add to Inquiry Basket

Surgical Gloves - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Layout

The powder-free and synthetic disposable latex gloves market is anticipated to thrive in the next three to five years due to increased healthcare spending and greater number of people being covered by insurance. The global market for disposable medical gloves generated $3 billion revenues in 2011. Marketstrat forecasts that this market will continue to expand at a compound annual growth of 4.9% exceeding $4.3 billion by 2018. Key market and technology drivers include concern over barrier protection, ease of use, tactility and comfort. This is the new emerging field and has a good domestic and international market. New entrepreneurs can well venture in this sector. Few Major Players are named as under: Bengal Waterproof Ltd. C E Gloves (India) Ltd. Casil Health Products Ltd. Casil Industries Ltd. Digiflex (India) Ltd. J K Ansell Ltd. London Rubber India Ltd. Mega Meditex Ltd. Sataytej Commercial Co. Ltd. Shiva Medicare Ltd. T T K Biomed Ltd.
Plant capacity: 6000000 Pairs/AnnumPlant & machinery: Rs.154 Lakhs
Working capital: -T.C.I: Cost of Project: Rs.323 Lakhs
Return: 23.00%Break even: 48.00%
Add to Inquiry Add to Inquiry Basket

Pharmaceutical Unit(Automatic Plant of Tablet and Capsule) - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market, with market leader holding nearly 7% of the market share. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs etc. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade. The Indian pharmaceutical industry is the fourth largest in the world in terms of volume of output and thirteenth in domestic demand. The domestic market is estimated at Rs 680 bn. The key categories driving growth are the traditionally largest segment - anti-infective and gastro-intestinal, drugs, which expanded by 22% and 19% respectively. Fast sales growth is also visible in categories like respiratory (18%), cardiac (14%), neurology (20%) and anti-diabetic (19%). The number of product launches exceeds 2,000 annually. Both MNC and Indian companies are implementing strategies which will help them to benefit from and cope with the developing patent regime. India has the highest number of (US Food and Drug Administration) USFDA approved manufacturing facilities outside the US and this puts India in good position to export to regulated markets. The major players in the country are: Aanjaneya Lifecare Ltd. Aashi Industries Ltd. Abbott India Ltd. Advik Laboratories Ltd. Aesculapius Remedies Ltd. Ajanta Pharma Ltd. Albert David Ltd. Alkem Laboratories Ltd. Alpa Laboratories Ltd. Ambalal Sarabhai Enterprises Ltd. Amee Cosmo Pharma Ltd. American Remedies Ltd. Amstrin Healthcare Ltd. Anan Drug & Chem Ltd. Andre Laboratories Ltd. Anglo-French Drugs & Inds. Ltd. Ankur Drugs & Pharma Ltd. Anmol Drugs & Pharmaceuticals Ltd. Anuh Pharma Ltd. Apex Laboratories Ltd. Apple Laboratories Ltd. Armour Chemicals Ltd. Arvind Remedies Ltd. Astrazeneca Pharma India Ltd. Astron Drugs & Inds. Ltd. Aurobindo Pharma Ltd. Aventis Pharma Ltd. B D H Industries Ltd. Bafna Pharmaceuticals Ltd. Bal Pharma Ltd. Basav Chem Ltd. Bassein Drugs Ltd. Beem Healthcare Ltd. Bengal Immunity Ltd. Beryl Drugs Ltd. Bharat Parenterals Ltd. Bharat Serums & Vaccines Ltd. Biddle Sawyer Ltd. Bio-Ethicals Pharma Ltd. Biocon Biopharmaceuticals Pvt. Ltd. Biocon Ltd. Biofil Chemicals & Pharmaceuticals Ltd. Biological E. Ltd. Blue Cross Laboratories Ltd. Boehringer Mannheim India Ltd. Brabourne Enterprises Ltd. Bravo Healthcare Ltd. Brawn Biotech Ltd. Burroughs Wellcome (India) Ltd. Cadila Healthcare Ltd. Cadila Laboratories Pvt. Ltd. Cadila Pharmaceuticals Ltd. Caplin Point Laboratories Ltd. Caryl Laboratories Ltd. Casil Industries Ltd. Celestial Biolabs Ltd. Centaur Pharmaceuticals Pvt. Ltd. Cepham Organics Ltd. Cepham Pharmaceuticals Ltd. Chemech Laboratories Ltd. Chemosyn Ltd. Ciba Ckd Biochem Ltd. Claris Lifesciences Ltd. Colinz Laboratories Ltd. Combat Drugs Ltd. Concept Pharmaceuticals Ltd. Concord Biotech Ltd. Concord Drugs Ltd. Coral Laboratories Ltd. Core Laboratories Ltd. Cosme Farma Laboratories Ltd. Cosme Pharma Ltd. Creative Health Care Pvt. Ltd. Croslands Research Laboratories Ltd. Croydon Chemical Works Ltd. Curewell (India) Ltd. Damania Pharma Ltd. Deepharma Laboratories Ltd. Deepharma Ltd. Dey'S Medical Stores Mfg. Ltd. Dishman Pharmaceuticals & Chemicals Ltd. Dolphin Laboratories Ltd. Dr. Reddy'S Laboratories Ltd. Druid Pharma Ltd. Dujohn Laboratories Ltd. Dumex Ltd. Eaco Labs Ltd. Earnest Healthcare Ltd. East India Pharmaceutical Works Ltd. Ebers Pharmaceuticals Ltd. Elder Health Care Ltd. Elder Pharmaceuticals Ltd. Elder Projects Ltd. Elvina Pharmaceuticals Ltd. Emaai Pharma Ltd. Emcure Pharmaceuticals Ltd. Endo Labs Ltd. Entod Pharmaceuticals Ltd. Esskay Pharmaceuticals Ltd. Ethnor Ltd. Eupharma Laboratories Ltd. Everest Organics Ltd. Evid & Co. Chemicals Ltd. F D C Ltd. Fine Drugs & Chemicals Ltd. Flamingo Pharmaceuticals Ltd. Fredun Pharmaceuticals Ltd. Fresenius Kabi Oncology Ltd. Fulford (India) Ltd. Geno Pharmaceuticals Ltd. Gentech Laboratories Ltd. Geoffrey Manners & Co. Ltd. German Remedies Ltd. Glaxosmithkline Pharmaceuticals Ltd. Glen mark Exports Ltd. Glen mark Generics Ltd. Glen mark Laboratories Ltd. Glen mark Pharmaceuticals Ltd. Global Remedies Ltd. Goa Antibiotics & Pharmaceuticals Ltd. Group Pharmaceuticals Ltd. Guardian Health Care Ltd. Gufic Biosciences Ltd. Gujarat Inject Ltd. Gujarat Terce Laboratories Ltd. Gujarat Themis Biosyn Ltd. H O D Laboratories Ltd. Hab Pharmaceuticals & Research Ltd. Haffkine Ajintha Pharmaceuticals Ltd. Hallmark Healthcare Ltd. Harleystreet Pharmaceuticals Ltd. Health Care Ltd. Hexone Pharmaceuticals Ltd. Hindustan Max-Gb Ltd. Hub Pharmaceuticals Pvt. Ltd. I D P L (Tamil Nadu) Ltd. Icon Biopharma & Healthcare Ltd. Icpa Health Products Ltd. Idma Laboratories Ltd. Ind-Swift Laboratories Ltd. Ind-Swift Ltd. India Infusion Ltd. Indian Drugs & Pharmaceuticals Ltd. Indoco Healthcare Ltd. Indoco Remedies Ltd. Indon Healthcare Ltd. Innotech Pharma Ltd. Intas Pharmaceuticals Ltd. Intercare Limited Intercare Ltd. International Drug Co. Ltd. Inventia Healthcare Pvt. Ltd. Inwinex Pharmaceuticals Ltd. Ipca Laboratories Ltd. Ivee Injectaa Ltd. J B Chemicals & Pharmaceuticals Ltd. J K Pharmachem Ltd. Jagsonpal Exports India Pvt. Ltd. Jagsonpal Pharmaceuticals Ltd. Jenburkt Pharmaceuticals Ltd. Jilichem Laboratories (India) Ltd. John Wyeth (India) Ltd. Johnson & Johnson Ltd. Kabra Drugs Ltd. Kappac Pharma Ltd. Karnataka Antibiotics & Pharmaceuticals Ltd. Kee Pharma Ltd. Kilitch Drugs (India) Ltd. Konkan Capsules Ltd. Krebs Biochemicals & Inds. Ltd. Labinduss Ltd. Lekar Healthcare Ltd. Lekar Pharma Ltd. Lincoln Pharmaceuticals Ltd. Liva Healthcare Ltd. Lordvin Labs Ltd. Lupin Laboratories Ltd. Lupin Ltd. Lyka B D R International Ltd. Lyka Labs Ltd. Lympha Laboratories Ltd. M J Pharmaceuticals Ltd. Macleods Pharmaceuticals Ltd. Maharashtra Antibiotics & Pharmaceuticals Ltd. Makers Laboratories Ltd. Maneesh Pharmaceuticals Ltd. Manipur State Drugs & Pharmaceuticals Ltd. Marck Biosciences Ltd. Mars Life Sciences Ltd. Martin & Harris Laboratories Ltd. Max India Ltd. Mayank & Lili Pharma Ltd. Mayo (India) Ltd. Mcneil & Argus Pharmaceuticals Ltd. Medicamen Biotech Ltd. Medispan Ltd. Medley Pharmaceuticals Ltd. Meghdoot Chemicals Ltd. Meher Pharma (India) Ltd. Merck Ltd. Mercury Laboratories Ltd. Mercury Phytochem Ltd. Merind Ltd. Mesco Pharmaceuticals Ltd. Metropolitan Overseas Ltd. Micro Labs Ltd. Monarch Laboratories Ltd. Morepen Laboratories Ltd. Mount Mettur Pharmaceuticals Ltd. N B Z Pharma Ltd. N R Jet Enterprises Ltd. Natco Pharma Ltd. Nem Organics Ltd. Neon Laboratories Ltd. Nestor Pharmaceuticals Ltd. Neulife Laboratories Ltd. Nirma Ltd. Nitya Laboratories Ltd. Novartis India Ltd. Novus Pharmaceuticals Ltd. Om Pharmaceuticals Ltd. Omega Biotech Ltd. Omega Laboratories Ltd. Onco Therapies Ltd. Opec Innovations Ltd. Orchid Chemicals & Pharmaceuticals Ltd. Organon (India) Ltd. Ozone Pharmaceuticals Ltd. P C I Chemicals & Pharmaceuticals Ltd. Paam Pharmaceuticals (Delhi) Ltd. Panacea Biotec Ltd. Parabolic Drugs Ltd. Paras Pharmaceuticals Ltd. Parke-Davis (India) Ltd. Penam Laboratories Ltd. Perk Pharmaceuticals Ltd. Pfimex Pharmaceuticals Ltd. Pfizer Ltd. Phaarmasia Ltd. Phar-East Laboratories Ltd. Pharmacia Healthcare Ltd. Pharmaids Pharmaceuticals Ltd. Pharmax Corporation Ltd. Pharmed Ltd. Phyto Specialities Pvt. Ltd. Plethico Pharmaceuticals Ltd. Procter & Gamble Hygiene & Health Care Ltd. Quality Pharmaceuticals Ltd. R P G Life Sciences Ltd. Rajasthan Drugs & Pharmaceuticals Ltd. Rajat Pharmachem Ltd. Ranbaxy Drugs Ltd. Ranbaxy Laboratories Ltd. Raptakos, Brett & Co. Ltd. Ravish Infusions Ltd. Reckitt Benckiser (India) Ltd. Rekvina Laboratories Ltd. Resonance Specialties Ltd. Rhone-Poulenc (India) Ltd. Rolex Pharmaceuticals Ltd. Rosemount Pharma India Ltd. Rubra Medicaments Ltd. Rupal Chemical Inds. Ltd. Rusan Pharma Ltd. S A M Biotech Ltd. Saket Projects Ltd. Sandoz (India) Ltd. [Amalgamated] Sanjeevanee Pharmaceuticals Ltd. Sanjivani Paranteral Ltd. Sanofi-Synthelabo (India) Ltd. Sarabhai Piramal Pharmaceuticals Pvt. Ltd. Sarala Pharmaceuticals Ltd. Sarthi Pharmaceuticals Ltd. Sarvodaya Labs Ltd. Schering-Plough (India) Pvt. Ltd. Senbo Industries Ltd. Shalina Laboratories Pvt. Ltd. Sharvani Pharmaceuticals Ltd. Shiv Herbal Research Laboratory Ltd. Sidmak Laboratories (India) Pvt. Ltd. Sigma Laboratories Ltd. Smith Stanistreet Pharmaceuticals Ltd. Smithkline Beecham Pharmaceuticals (India) Ltd. [Amalgamated] Solumiks Herbaceuticals Ltd. Sri Chakra Remedies Ltd. Sri Krishna Drugs Ltd. Sri Krishna Pharmaceuticals Ltd. Strides Arcolab Ltd. Sun Pharmaceutical Inds. Ltd. Surya Pharmaceutical Ltd. Sustime Pharma Ltd. Suyog Pharmaceuticals Pvt. Ltd. Swega Laboratories Ltd. Swet-Chem Antibiotics Ltd. Syncom Formulations (India) Ltd. Syncom Healthcare Ltd. T K Healthcare Ltd. Tablets (India) Ltd. Tamilnadu Dadha Pharmaceuticals Ltd. Targof Pure Drugs Ltd. Taulis Pharma Ltd. Teem Laboratories Ltd. Themis Medicare Ltd. Tonira Pharma Ltd. Torrent Pharmaceuticals Ltd. Toshvin Industries Ltd. Trans Medicare Ltd. Travel Co. In Pvt. Ltd. Troika Pharmaceuticals Ltd. Twilight Litaka Pharma Ltd. U S V Ltd. Uni-Sankyo Ltd. Uni-Ucb Ltd. Unibios Laboratories Ltd. Unichem Laboratories Ltd. Unicorn Pharmaceuticals (India) Ltd. Unimark Remedies Ltd. Unimed Investments Ltd. Unimed Technologies Ltd. Unique Pharmaceutical Laboratories Ltd. Universal Generics Ltd. Universal Pharmaceuticals Ltd. Unjha Formulations Ltd. Vellanova Pharmaceuticals Ltd. Venkat Pharma Ltd. Veronica Laboratories Ltd. Vista Pharmaceuticals Ltd. Vita Biopharma Pvt. Ltd. Vysali Pharmaceuticals Ltd. Wallace Pharmaceuticals Ltd. Wander Pvt. Ltd. Warren Pharmaceuticals Ltd. Welcure Drugs & Pharmaceuticals Ltd. White Way Products (Pharma) Ltd. Win-Medicare Pvt. Ltd. Wintac Ltd. Wockhardt’s Ltd. Wyeth Laboratories Ltd. Wyeth Ltd. Yogi Healthcare Ltd. Zenith Health Care Ltd. Zenotech Laboratories Ltd. Zillion Pharmachem Ltd. Zim Laboratories Ltd. Zuventus Healthcare Ltd. Zydus Animal Health Ltd. Zydus Pathline Ltd.
Plant capacity: 117 Lakhs Nos. /annumPlant & machinery: Rs. 125 Lakhs
Working capital: -T.C.I: Cost of Project: Rs. 1340 Lakhs
Return: 43.47%Break even: 54.86%
Add to Inquiry Add to Inquiry Basket

Market Research Report on Medical Devices & Surgical Disposables in India - Detailed Project Report, Profile, Business Plan, Trends, Market Research, Survey, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Working Capital

Market Research Report on Medical Devices & Surgical Disposables in India (Disposable Plastic Syringes, Blood Bags, X-Ray, Ultrasound, ECG, Pacemakers, IV Fluid Sets and Other Devices) Present & Future Prospects, Market Analysis, Statistics, Trends & Opportunities, Growth Drivers, SWOT Analysis, Industry Size, Outlook and Forecasts Upto 2017 The Market Research Report on MEDICAL DEVICES & SURGICAL DISPOSABLES IN INDIA (Disposable Plastic Syringes, Blood Bags, X-Ray, Ultrasound, ECG, Pacemakers, IV Fluid Sets and Other Devices) Present & Future Prospects, Market Analysis, Statistics, Trends & Opportunities, Growth Drivers, SWOT Analysis, Industry Size, Outlook and Forecasts Upto 2017’ released by Niir Project Consultancy Services, provides a comprehensive analysis on the medical device industry in India. The report begins with the global scenario of the medical device industry including market size forecasts till 2017 and eventually unwraps with the Indian scenario of the medical device and surgical disposable industry. The report elucidates the structure of Indian medical device industry, its classification in various risk classes and its segmentation into various sub-segments. Key segments include diagnostic imaging, dental products, disposables, orthopedic & prosthesis, IV diagnostics and patient aids. The reports also names various sub segments of the above mentioned segments. The report provides an expansive market analysis of the Indian medical device sector by covering areas like growth drivers, trends prevailing in the industry, regulatory framework as well as comprehensive SWOT analysis of the sector. The report provides an elaborative analysis of the factors which are and will be driving the growth of the industry. Such factors include burgeoning medical tourism in the country, vigorous growth of the hospital sector, increasing government focus towards medical device sector, India’s increasing life expectancy, rising health awareness among the Indian population as well as the rise in the incidence of lifestyle diseases in the nation. The trends prevalent in the industry as identified by the report includes increased inflow of investments in the sector, growing merger & acquisition activity, rise in demand of refurbished medical devices and new found focus on increasing the manufacturing base of such devices in the country. Industry players nowadays are expanding and focusing more on affordable manufacturing of medical devices in order to tap the rising demand from tier-II and tier-III cities. The report further establishes the regulatory framework of the industry. It encapsulates the status of the current legislation in the industry as well as the recent changes and developments in the regulations. The industry is awaiting the much anticipated approval of the Drugs & Cosmetics (Amendment) Bill, 2013 which will stabilize the regulatory environment for the industry. The report also contains key features of such above mentioned bill and enumerates various governing bodies of the sector. The report further explicates the SWOT analysis of the sector. The sector is placed in a sweet spot due to ready availability of abundant market base for its products in the form of rising Indian population. Additionally, Indian population distribution has been experiencing a gradual tilt towards the 25-59 & 60+ age groups which forms the key customers for the sector. Healthcare industry in India is a recession proof industry to some extent and medical device sector being a part of such industry benefits immensely from its growth as well as its relatively recession proof nature. The industry faces many challenges in the form of increasing competition in the sector, low penetration of healthcare in the nation, lack of funding and lack of required skill set. Despite such challenges, India is a sea of opportunities for the sector owing to the rising disposable incomes of the people which will lead to better healthcare penetration, rising government expenditure on the healthcare sector as a whole and low consumption of medical devices in the nation. The next segment of the report details the market potential of various sub segments of the sector. It includes demand analysis and key forecasts of X-Ray equipment, ultrasound equipment, disposable syringes, disposable blood bags, pacemakers, IV fluid sets and ECG equipment also. Further the report provides information on companies like Wipro GE Healthcare Pvt Ltd, Hindustan Syringes & Medical Devices Ltd and Opto Circuits (India) Ltd. The report shares vital information like shareholding pattern and financial summary of the key companies. The next segment provides complete financial comparison of medical device companies in India and buyers of medical devices (Hospitals). It covers contact information like address of registered office, key financials like plant location, raw material consumption and financial comparison covering balance sheet, profit & loss account and financial ratios. The industry has managed to reduce its dependency on imports and has expanded its manufacturing base owing to the towering demand experienced for affordable devices. The growth of healthcare sector in India will be a major boost for the device market. Rising incidence of lifestyle diseases due to changing lifestyles of Indian population and lack of physical exercise will be another feather in the hat. Other factors that will contribute to its glory are favorable demographics, increasing government focus on the sector, rapid spread of the health awareness and India emerging as the medical tourism hub of the world. On the back of the above mentioned factors the size of the Indian medical device industry will jump to INR 761 billion by 2017 registering a CAGR of 20% during 2012-17. Reasons for Buying this Report: • This research report helps you get a detail picture of the industry by providing overview of the industry along with the market structure and classification • The report provides market analysis covering major growth driving factors for the industry, latest market trends and regulatory framework of the industry • This report helps to understand the present status of the industry by elucidating a comprehensive SWOT analysis and scrutiny of the demand situation • Report provides analysis and in-depth financial comparison of major players/competitors • Report provides indispensable buyers data with their company financials as well as the contact details, which can be an important tool in identifying the target customers. • The report provides forecasts of key parameters which helps to anticipate the industry performance Our Approach: • Our research reports broadly cover Indian markets, present analysis, outlook and forecast for a period of five years. • The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players • We use reliable sources of information and databases. And information from such sources is processed by us and included in the report TABLE OF CONTENTS 1. OVERVIEW 1.1 Global Medical Device Industry 1.2 Indian Medical Device Industry 1.2.1 Classification of the Industry 2. MARKET ANALYSIS 2.1 Industry Growth Drivers 2.1.1 Burgeoning medical tourism 2.1.2 Growth of the hospital sector 2.1.3 Rising Health Awareness 2.1.4 Escalating Incidence of Lifestyle Diseases 2.1.5 Rising Life Expectancy 2.1.6 Increased Government Focus 2.2 Emerging Trends in the Industry 2.2.1 Refurbished Equipment 2.2.2 Increasing Investments 2.2.3 Rising Mergers & Acquisitions 2.2.4 Focus on Affordable Manufacturing 2.3 Regulatory Framework & Government Initiatives 2.3.1 Status of Regulations 2.3.2 Governing Bodies 2.4 SWOT Analysis 2.4.1 Strengths 2.4.1.1 Ready Market Base 2.4.1.2 Favorable Demographics 2.4.1.3 Part of the Recession Proof Industry 2.4.2 Weaknesses 2.4.2.1 Improper Legislation 2.4.2.2 Lack of Funding and R&D 2.4.2.3 Lack of Trained Personnel 2.4.3 Opportunities 2.4.3.1 Growing Disposable Incomes 2.4.3.2 Government Spending on Healthcare 2.4.3.3 Low Medical Device Penetration 2.4.4 Threats 2.4.4.1 Competition 2.4.4.2 Low Healthcare Penetration 3. MARKET POTENTIAL 3.1 ECG Equipment 3.2 Disposable Syringe 3.3 Disposable Blood Bags 3.4 X-Ray Equipment 3.5 Ultrasound Equipment 3.6 IV Fluid Sets 3.7 Pacemakers 4. KEY PLAYERS 4.1 Hindustan Syringes & Medical Devices Ltd 4.2 Opto Circuits (India) Ltd 4.3 Wipro GE Healthcare Pvt Ltd 5. KEY FINANCIALS & ANALYSIS 5.1 Players in the Segment 5.1.1 Contact Information 5.1.1.1 Registered Office Address 5.1.1.2 Director’s Name 5.1.2 Key Financials 5.1.2.1 Plant Location 5.1.2.2 Raw Material Consumption 5.1.2.3 Plant Capacity & Sales 5.1.3 Financial Comparison 5.1.3.1 Assets 5.1.3.2 Liabilities 5.1.3.3 Growth in Assets & Liabilities 5.1.3.4 Structure of Assets & Liabilities 5.1.3.5 Income & Expenditure 5.1.3.6 Growth in Income & Expenditure 5.1.3.7 Profits 5.1.3.8 Liquidity Ratios 5.1.3.9 Profitability Ratios 5.1.3.10 Return Ratios 5.1.3.11 Working Capital & Turnover Ratios 5.2 Buyers of the Industry’s Product 5.2.1 Registered Office Address 5.2.2 Financial Comparison 5.2.2.1 Assets 5.2.2.2 Liabilities 5.2.2.3 Income & Expenditure 6. INDUSTRY SIZE & OUTLOOK LIST OF FIGURES & TABLES Figure 1 Global Medical Device Industry- Market Size (2006-17, In USD Billions) Figure 2 Indian Medical Device Industry- Structure Figure 3 Indian Medical Device Industry- Segmentation Figure 4 Medical Tourist Arrivals in India (2005-15E, In Nos.) Figure 5 Indian Hospital Sector- Market Size (2008-17, In USD Billions) Figure 6 Health Insurance Premium (FY08-13, In INR Billions) Figure 7 Per Capita Health Expenditure (2006-11, In USD) Figure 8 World Diabetics Statistics (In Millions) Figure 9 Percentage of Population with Lifestyle Diseases Figure 10 Population Distribution of India Figure 11 Private Equity Deals in Indian Medical Device Sector (FY08-14) Figure 12 Population of India (2008-17E, In Millions) Figure 13 Population Growth of 60+ years in India Figure 14 Indian Healthcare Industry- Market Size (2008-17, In USD Billions) Figure 15 India's Annual Per Capita Income (2008-13, In INR) Figure 16 Plan Outlay for Health Sector in 5 Year Plans (In INR Billions) Figure 17 Per Capita Expenditure on Medical Devices in Various Countries (In USD) Figure 18 Beds Per 1000 Population Figure 19 Demand for ECG Equipment in India (2008-17, In Units) Figure 20 Indian ECG Equipment Market- Industry Size (2008-17, In INR Millions) Figure 21 Demand for Disposable Syringes in India (2007-17, In Billion Nos) Figure 22 Demand for Disposable Blood Bags in India (2007-17, In Million Nos.) Figure 23 Demand for X-Ray Equipment in India (2009-17, In Units) Figure 24 Indian X-Ray Equipment Industry - Market Size (2008-17, In INR Millions) Figure 25 Demand for Ultrasound Equipment in India (2009-17, In Units) Figure 26 Indian Ultrasound Equipment Industry- Market Size (2009-17, In INR Millions) Figure 27 Demand for IV Fluid Sets in India (2007-17, In Million Bottles) Figure 28 Demand for Pacemakers in India (2007-17, In Nos.) Figure 29 Opto Circuits (India) Ltd- Shareholding Pattern (Dec 2013) Figure 30 Medical Device Industry in India- Market Size (2008-17, In INR Billions) Table 1 Classification of Medical Devices in India Table 2 Private Equity Investments in Indian Medical Device Sector (FY14) Table 3 Domestic Mergers & Acquisitions in the Sector Table 4 Outbound Mergers & Acquisitions in the Sector Table 5 List of Notified Medical Devices Table 6 Acquisitions by Opto Circuits (India) Ltd Table 7 Opto Circuits (India) Ltd- Financial Summary (2011-13) Table 8 Opto Circuits (India) Ltd- Segmental Performance (2010-13, In INR Millions)
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Pharmaceutical Unit (Tablets, Syrup & Injectables) - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunity

The Indian Pharmaceutical Industry today is in the front rank of India’s science-based industry with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations. India has the world's third largest active pharmaceutical ingredients (API) for the industry valued at a little less than USD 2 bn. Top 5 API producers account for approximately 6.5 %. Export growth is driven by growing dependence on generics across the world acceptance of Indian generic drugs, aggressive expansion of Indian companies in international markets and entry of smaller companies into exports. Global pharma companies are increasingly exploring low cost option to outsource research and manufacturing, because of emerging slow-down in patented drug sales and high cost of R&D. As a whole establishing Pharmaceutical Unit is one of the project which has good prospect for the entrepreneurs to invest. Few Indian Major Players are as under:- Abbott India Ltd. Anglo-French Drugs & Inds. Ltd. Biological E. Ltd. Boehringer Mannheim India Ltd. Cadila Laboratories Pvt. Ltd. Cadila Pharmaceuticals Ltd. Chemcel Biotech Ltd. Cosme Farma Laboratories Ltd. Fermenta Biotech Ltd. H P M Industries Ltd. Indian Drugs & Pharmaceuticals Ltd. Inventia Healthcare Pvt. Ltd. M S T C Ltd. Mayo (India) Ltd. Neo Corp Intl. Ltd. Northern Minerals Ltd. Pharmacia Healthcare Ltd. Rhyme Organics & Chemicals Ltd. Sandoz (India) Ltd. Sanofi India Ltd.
Plant capacity: 69 Lakh Nos./Annum,Bruphen Tablets(10 Pcs):9 Lakh Nos./Annum (Strips),Paracetamol Syrup: 24 Lakh Nos./Annum (Bottles),Dextrose Saline: 18 Lakh Nos./Annum (Bottles),Streptomycine Injection: 18 Lakh Nos./Annum (Bottles)Plant & machinery: Rs. 112 Lakhs
Working capital: -T.C.I: Cost of Project: Rs. 584 Lakhs
Return: 27.00%Break even: 55.00%
Add to Inquiry Add to Inquiry Basket

Surgical Cotton & Bandages - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue

Surgical Bandages are the products manufactured from White Bleached Cotton gauge Cloth of suitable quality. These are available in various widths of running from 2.5 cm to 15 cms and of length from 3 meters or 4 meters. These are mainly used in hospital/Dispensaries for tying the wounds after dressing. The Function of bandages is to hold dressings in place to provide pressure or support. They may be inelastic, elastic, or become rigid after shaping for immobilization. Surgical Cotton is mainly used for cleaning and dressing the wounds by Doctor and Jauhrus's. It is also used by Tailors for putting pads in Woolen Suits etc. and making Novelties items by artists. Of course the Doctors consume the maximum quantity of Surgical Cotton produced in India. In present much advanced time the numbers of doctors are increasing drastically thereby increasing demand for surgical cotton at very fast rate. It also carried a good potential. Medium staple cottons, Boned was to from cotton Mills or Linters from spinning Mills are used as raw materials for the manufacture of this product. To manufacture surgical cotton anyone of these three materials may be used separately or farley economical blend produce good quality surgical cotton. The demand of Surgical Absorbent Cotton is directly related with the increase in population and expansion of public health services. The demand for Surgical Absorbent Cotton increases with the increase in population and number of hospitals, dispensaries, nursing homes, health care centers etc. Progressive increase in health amenities offered by Government and coming up of new hospitals and health care centres in private sector even at small towns are contributing to the growth of absorbent cotton industry. Government hospitals and large nursing homes are the largest consumer for cotton wool. Surgical cotton or absorbent cotton is in great demand all over the world, but with desi cotton — considered ideal raw material for it — being edged out, manufacturers have been banking heavily on regular American cotton. As a whole it is a good project for entrepreneurs for investment. Few Indian Major Players are as under:- Add-Life Pharma Ltd. Beiersdorf India Ltd. Bengal Chemicals & Pharmaceuticals Ltd. Casil Health Products Ltd. Datt Mediproducts Ltd. Dr. Sabharwal'S Manufacturing Labs Ltd. Goldwin Medicare Ltd. Johnson & Johnson Ltd. Lavino Kapur Cottons Pvt. Ltd. Ramaraju Surgical Cotton Mills Ltd.
Plant capacity: Surgical Cotton: 3 Lakh Kgs/Annum,Surgical Bandages: 9 Lakh Pcs/AnnumPlant & machinery: Rs. 81 Lakhs
Working capital: -T.C.I: Cost of Project : Rs. 165 Lakhs
Return: 24.00%Break even: 53.00%
Add to Inquiry Add to Inquiry Basket

Hard Gelatin Capsules - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue

Capsules are solid dosage forms in which one or more medicinal and inert ingredients are enclosed in a small shell or container usually made of gelatin. There are two types of capsules, “hard” and “soft”. The hard capsule is also called “two piece” as it consists of two pieces in the form of small cylinders closed at one end; the shorter piece is called the “cap” which fits over the open end of the longer piece, called the “body”. The soft gelatin capsule is also called as “one piece”. Capsules are available in many sizes to provide dosing flexibility. Unpleasant drug tastes and odors can be masked by the tasteless gelatin shell. Gelatin is defined as a product obtained by the partial hydrolysis of collagen derived from the skin white connective tissue and bones of animals. Gelatin derived from an acid treated pre curser is known as type A and gelatin derived from an alkali treated precursor is known as type B. Gelatin is a protein and in aqueous solution forms a hydrophilic colloid, leading to complex behavior. As a normal constituent of plant and animal tissues, it is essential to their growth. It occurs especially in seeds, the yolk of eggs, the nerves and brain and bone narrow, usually in the form of lecithins or glycero phosphates. It is an essential constituent of bones in the format calcium phosphate. Bone contains about 58% calcium phosphate plus some calcium carbonate, fat and nitrogenous organic matter. Hard gelatin capsules are a modern dosage form for medicinal use, stemming from the increased emphasis on pharmacokinetics found in drug development today. This has considerably expanded the range of possible formulations utilizing hard gelatin capsules as a simple dosage form for oral drug delivery. The Indian pharmaceutical industry is the fourth largest in the world in terms of volume of output and thirteenth in domestic demand. However, the Indian industry, valued at USD 17 bn in represented just over 1% of the global pharmaceutical industry (USD 1700 bn) in value terms. The domestic market is estimated at Rs 680 bn. India has the world's third largest active pharmaceutical ingredients (API) for the industry valued at a little less than USD 2 bn. Top 5 API producers account for approximately 6.5 %. The leading APIs are anti-infectives, gastrointestinal, cardiovascular and respiratory drugs. Any entrepreneurs venture into this field will be successful. Few Indian Major Players are as under:- A B L Biotechnologies Ltd. A C G Arts & Properties Pvt. Ltd. Akums Drugs & Pharmaceuticals Ltd. Capsugel Healthcare Ltd. Chemcaps Ltd. Dinesh Remedies Ltd. Emcure Pharmaceuticals Ltd. Healthcaps India Ltd. Indian Drugs & Pharmaceuticals Ltd. Maxcure Nutravedics Ltd. Medi-Caps Ltd. Natural Capsules Ltd. Sunil Healthcare Ltd.
Plant capacity: 450000 Th.Nos./AnnumPlant & machinery: Rs. 295 Lakhs
Working capital: -T.C.I: Cost of Project : Rs. 549 Lakhs
Return: 12.00%Break even: 56.00%
Add to Inquiry Add to Inquiry Basket

IV (intravenous) Fluids [Form Fill Seal (FFS) Technology] - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Plant Layout

Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to protect patients from injury, and there are a number of different types available for use. Many companies manufacture packaged intravenous fluids, as well as products which can be mixed with sterile water to prepare a solution for intravenous administration. Intravenous fluids can be broken into two broad groups. Crystalloids such as saline solutions contain a solution of molecules which can dissolve in water. When crystalloids are administered, they tend to create low osmotic pressure, allowing fluid to move across the blood vessels, and this can be linked with edema. Colloids contain particles which are not soluble in water, and they create high osmotic pressure, attracting fluid into the blood vessels. Blood is an example of a commonly administered intravenous colloid. I.V. fluid demand is normally linked to the number of hospital beds. Observations show that 18 bottles of I.V. fluids are consumed per bed per month in the country. The demand is estimated to increase at a rate of 9 to 12% per annum. The present demand level is estimated to be around 2200 Lakh bottles per annum. Areas with high population density and average temperatures are major consumption areas of I.V. fluids. Demand is high Uttar Pradesh, Rajasthan, Haryana, Bihar, Madhya Pradesh and West Bengal. North India alone account for one third of the total demand in the country. So any new entrants can venture in to this industry. Few Indian Major Players are as under:- Ahlcon Parenterals (India) Ltd. Core Laboratories Ltd. Gujarat Ambuja Proteins Ltd. Gujarat Inject Ltd. Haffkine Bio-Pharmaceutical Corpn. Ltd. India Infusion Ltd. Indian Maize & Chemicals Ltd. K G Gluco Biols Ltd. Kamala Sugar Mills Ltd. Kokad Pharmaceutical Laboratories Ltd. Marck Biosciences Ltd. Origin Agrostar Ltd. Parenteral Surgicals Ltd. Senbo Industries Ltd. Span Medicals Ltd. Tirupati Starch & Chemicals Ltd. Unique Sugars Ltd. Wockhardt Health Care Ltd.
Plant capacity: 144 Lakh Bottles/AnnumPlant & machinery: Rs. 808 Lakhs
Working capital: -T.C.I: Cost of Project : Rs. 1367 Lakhs
Return: 25.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Dextrose Powder - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Layout

Dextrose in food is a simple sugar. It is actually a type of glucose, which is a monosaccharide that is widely found in nature and is used by nearly every living organism as a source of energy at the cellular level. The glucose molecule comes in two molecular forms that are mirror images of one another, and dextrose is one of those forms. Dextrose (or D-Glucose) is a simple hexose mono-saccharide sugar. It is so called because it turns the plane of polarization to the right. Entirely derived from corn it is free from all other sugars and starches, proteins, alcohols and heavy metals. It is the natural form of Glucose. Dextrose is a form of glucose, a monosaccharide, or simple sugar. Glucose is your body's primary fuel, and while your digestive system can break down all the foods that you eat into glucose, carbohydrates provide the most amount of raw materials for glucose. Glucose molecules can occur in two different shapes, known as stereoisomers, and one of those forms is called dextrorotary glucose. It's also known by the chemical name of dextrose monohydrate, or d-glucose for short. The food industry calls this sugar dextrose. The demand for dextrin and dextrose is highly influenced by the growth of the manufacturing sectors mainly textiles, glass, printing ink, food, soft drink, tanning, tobacco and the like. The manufacturing sector has been growing by more than 6% in the past few years. Assuming the past trend will continue in the future, an annual average growth rate of 6% is applied to forecast the future demand by taking the current effective demand as a base. So any new entrants can venture in to this industry. Few Indian Major Players are as under:- Gujarat Ambuja Proteins Ltd. Indian Maize & Chemicals Ltd. K G Gluco Biols Ltd. [Merged] Kamala Sugar Mills Ltd. Origin Agrostar Ltd. Tirupati Starch & Chemicals Ltd. Unique Sugars Ltd. Wockhardt Health Care Ltd.
Plant capacity: 9000 MT/AnnumPlant & machinery: Rs. 1359 Lakhs
Working capital: -T.C.I: Cost of Project : Rs. 1954 Lakhs
Return: 22.00%Break even: 49.00%
Add to Inquiry Add to Inquiry Basket

Disposable Plastic Syringes - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue

A syringe is a simple piston pump consisting of a plunger that fits tightly in a tube. The plunger can be pulled and pushed along inside a cylindrical tube (the barrel), allowing the syringe to take in and expel a liquid or gas through an orifice at the open end of the tube. The open end of the syringe may be fitted with a hypodermic needle, a nozzle, or tubing to help direct the flow into and out of the barrel. Disposable Syringes made of plastic Material have been successfully used in medical and pharmaceutical practice for many years. The constantly increasing use of this type Syringe indicates its importance, which is based mainly on the advantages it offers regarding cost and hygienic applications. Disposable syringes commonly are used in modern medicine for the injection of drugs and vaccines or for the extraction of blood. The often are used instead of reusable syringes in an effort to avoid spreading a disease. Among the common uses of disposable syringes are the injecting of insulin by a diabetic person and the administering of a local anesthesia by a dentist. The market for non-premium equipments, appliances and disposables is, however, dominated by the domestic manufacturers, while foreign suppliers and Indian companies with foreign alliances dominate the high-end hi-tech medical equipment and appliances. Among the leading providers of advanced products are Siemens, GE, Philips Medical Systems, Toshiba, Hitachi and Boston Scientific. So any new entrants can venture in to this industry. Few Indian Major Players are as under:- Albert David Ltd. Disposable Medi-Aids Ltd. H L L Lifecare Ltd. Hindustan Syringes & Medical Devices Ltd. Iscon Surgicals Ltd. La Medical Devices Ltd. Lifeline Injects Ltd. Lifelong Meditech Ltd. Nirma Ltd. Raaj Medisafe India Ltd. Sangam Health Care Products Ltd. Surgiplast Ltd.
Plant capacity: Syringes (2 ml) : 90 Lakh Nos. /Annum,Syringes (5 ml) : 90 Lakh Nos. /AnnumPlant & machinery: Rs. 245 Lakhs
Working capital: -T.C.I: Cost of Project : Rs. 455 Lakhs
Return: 26.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 13 of 21 | Total 201 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Section of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top